1.Rossi E., Piccini F., Zollino M., Neri G., Caselli D., Tenconi R, et al. Cryptic telomeric rearrangements in subjects with mental retardation associated with dysmorphism and congenital malformations. J Med Genet. 2001. 38:417–20.
Article
2.Willatt L., Cox J., Barber J., Cabanas ED., Collins A., Donnai D, et al. 3q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome. Am J Hum Genet. 2005. 77:154–60.
Article
3.Ballif BC., Theisen A., Coppinger J., Gowans GC., Hersh JH., Madan-Khetarpal S, et al. Expanding the clinical phenotype of the 3q29 microdeletion syndrome and characterization of the reciprocal micro-duplication. Mol Cytogenet. 2008. 1:8.
Article
4.Baynam G., Goldblatt J., Townshend S. A case of 3q29 microdeletion with novel features and a review of cytogenetically visible terminal 3q deletions. Clin Dysmorphol. 2006. 15:145–8.
Article
5.Genome Bioinformatics Group of UC Santa Cruz, UCSC genome browser. http://genome.ucsc.edu/cgi-bin/hgGateway. (Updated on Jan. 2009.
6.The Centre for Applied Genomics, Database of genomic variants. http://projects.tcag.ca/variation/?source=hg18. (Updated on Jan. 2009.
7.Online Mendelian Inheritance in Man. http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim. (Accessed on Jan. 2009.
8.Vissers LE., Veltman JA., van Kessel AG., Brunner HG. Identification of disease genes by whole genome CGH arrays. Hum Mol Genet. 2005. 14(Review Issue 2):R. 215–23.
Article
9.Ullmann R., Turner G., Kirchhoff M., Chen W., Tonge B., Rosenberg C, et al. Array CGH identifies reciprocal 16p13.1 duplications and deletions that predispose to autism and/or mental retardation. Hum Mutat. 2007. 28:674–82.
Article
10.Lupski JR. Genomic disorders: structural features of the genome can lead to DNA rearrangements and human disease traits. Trends Genet. 1998. 14:417–22.
Article
11.Inoue K., Lupski JR. Molecular mechanisms for genomic disorders. Annu Rev Genomics Hum Genet. 2002. 3:199–242.
Article
12.McCarroll SA., Hadnott TN., Perry GH., Sabeti PC., Zody MC., Barrett JC, et al. Common deletion polymorphisms in the human genome. Nat Genet. 2006. 38:86–92.
Article
13.Conrad DF., Andrews TD., Carter NP., Hurles ME., Pritchard JK. A high-resolution survey of deletion polymorphism in the human genome. Nat Genet. 2006. 38:75–81.
Article
14.Allen KM., Gleeson JG., Bagrodia S., Partington MW., MacMillan JC., Cerione RA, et al. PAK3 mutation in nonsyndromic X-linked mental retardation. Nat Genet. 1998. 20:25–30.
Article
15.Tarpey P., Parnau J., Blow M., Woffendin H., Bignell G., Cox C, et al. Mutations in the DLG3 gene cause nonsyndromic X-linked mental retardation. Am J Hum Genet. 2004. 75:318–24.
Article
16.Monahan P., Rybak S., Raetzman LT. The notch target gene HES1 regulates cell cycle inhibitor expression in the developing pituitary. Endocrinology. 2009. 150:4386–94.
17.Rochais F., Dandonneau M., Mesbah K., Jarry T., Mattei MG., Kelly RG. Hes1 is expressed in the second heart field and is required for outflow tract development. PLoS One. 2009. 4:e6267.
Article
18.Dunn LL., Sekyere EO., Rahmanto YS., Richardson DR. The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. Carcinogenesis. 2006. 27:2157–69.
Article
19.Sekyere EO., Dunn LL., Rahmanto YS., Richardson DR. Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. Blood. 2006. 107:2599–601.
Article